The difference in gastric cancer between Japan, USA and Europe: What are the facts? What are the suggestions?

Critical Reviews in Oncology/Hematology

Volumn 40, Issue 1, 2001, Pages 77-94

  Davis, Peter A ^a   Sano, Takeshi ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

D2; Gastrectomy; Gastric cancer; Racial difference; Radical lymphadenectomy; Stage migration

Indexed keywords

ADJUVANT THERAPY; BIODIVERSITY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EUROPE; GASTRECTOMY; HUMAN; HYPOTHESIS; JAPAN; LYMPHADENECTOMY; MIGRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH CARCINOMA; TREATMENT OUTCOME; UNITED STATES;

COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; EUROPE; HUMANS; JAPAN; NEOPLASM STAGING; STOMACH NEOPLASMS; SURVIVAL RATE; UNITED STATES;

EID: 0034830956     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00131-1     Document Type: Review

References (104)

1. Gastric carcinoma
2. Gastric cancer: Different diseases
3. Epidemiology of gastric cancer
4. Rising incidence of adenocarcinoma of the oesophagus and gastric cardia
5. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites
6. Does incidence of carcinoma of the oesophagogastric junction increase?
7. Classification of adenocarcinoma of oesophagogastric junction
8. Adenocarcinoma of the gastro-oesophageal junction in Japan: Relevance of Siewert's classification applied to 177 cases resected at a single institution
9. The two histological main types of gastric cancinoma: Diffuse and so called intestinal type carcinoma
10. Gastric cancer
11. Comparison of 'early gastric cancer' in Britain and Japan
12. Endoscopic diagnosis of intestinal metaplasia in Canada and Japan
13. Comparison of the molecular genetics of c-erb-B2 and p53 expression in stomach cancer in Britain and Japan
14. c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan
15. Are Japanese and European gastric cancer the same biological entity? An immunohistochemical study
16. Racial factors cannot explain superior Japanese outcomes in stomach cancer
17. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the 'different disease' hypothesis
18. Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients
19. Is the prognosis for Japanese and German patients with gastric cancer really different?
20. The influence of excess body weight on the surgical treatment of patients with gastric cancer
21. Japanese classification of gastric cancer: 2nd English edition
22. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer
23. Evaluation of the New American Joint Committee on Cancer/International Union against cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification
24. Evaluation of the new International Union Against Cancer TNM staging for gastric carcinoma
25. The macroscopic diagnosis of lymph node metastasis from early gastric cancer
26. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer
27. Gastric cancer
28. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients
29. Extended lymph-node dissection for gastric cancer
30. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries
31. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists
32. Diagnosis of gastric carcinoma: Japanese fairy tales or Western deficiency?
33. Differences in diagnostic criteria for gastric carcinoma between Japanese and Western pathologists
34. Evaluation of gastric biopsies for neoplasia: Differences between Japanese and Western pathologists
35. The Vienna classification of gastrointestinal epithelial neoplasia
36. Recurrence of early gastric cancer. Follow-up of 1475 patients and review of the Japanese literature
37. Is lymphadenectomy necessary for early gastric cancer?
38. Increasing incidence and excellent survival of patients with early gastric cancer: Experience in a United States medical center
39. Early gastric cancer: 46 Cases treated in one surgical department
40. Cancer screening-past, present and future. Report of 13th international conference
41. Screening for gastric cancer
42. Surgical treatment of gastric cancer detected by mass screening
43. Early gastric cancer: Endoscopic diagnosis of depth of invasion
44. Endoscopy
45. Early detection of gastric cancer
46. Detection of early gastric cancer in an aggressive endoscopy unit
47. Minute and small early gastric cancers in a Western population: A clinicopathologic study
48. Can we improve the uptake of gastroscopy in the population at risk for gastric cancer? The effect of home letter information
49. Surgery for gastric cancer: The American view
50. Laparoscopy and laparoscopic ultrasound in the staging of gastric cancer
51. Laparoscopy in the management of gastric adenocarcinoma
52. Laparoscopic staging of gastric cancer is safe and affects treatment strategy
53. Prognostic significance and surgical management of lymph node metastasis in gastric cancer
54. Progress in gastric cancer surgery in Japan and its limits of radicality
55. Computer analysis in making preoperative decisions: A rational approach to lymph node dissection in gastric cancer patients
56. New trends in surgery for gastric cancer in Japan
57. Low operative morbidity and mortality in extended lymphadenectomy for gastric cancer in Japan
58. Description of the Japanese method of radical gastrectomy
59. Extended lymphadenectomy in gastric cancer: When, for whom and why
60. D2 dissection for gastric cancer
61. Cancer of the stomach. A patient care study by the American College of Surgeons
62. Inadequate documentation and resection for gastric cancer in the United States: A preliminary report
63. Amylase concentration of drainage fluid after total gastrectomy
64. Pancreas-preserving total gastrectomy for proximal gastric cancer
65. Lack of benefit of combined pancreaticosplenectomy in D2 resection for proximal-third gastric carcinoma (invited commentary)
66. Redefining surgery for gastric cancer
67. Lymphadenectomy for gastric cancer in clinical trials: Update
68. Subtotal versus total gastrectomy for cancer of the lower two-thirds of the stomach: A new approach to an old problem
69. Total or subtotal gastrectomy for gastric cancer? A study of quality of life
70. Randomised comparison of R1 and R2 gastrectomy for gastric carcinoma
71. A prospective randomised trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer
72. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German gastric carcinoma study group
73. Factors influencing noncompliance and contamination in a randomized trial of 'Western' (r1) versus 'Japanese' (r2) type surgery in gastric cancer
74. Evaluation of the extent of lymphadenectomy in a randomized trial of Western- versus Japanese-type surgery in gastric cancer
75. Lymph node staging standards in gastric cancer
76. Lymph node retrieval in a randomized trial on western-type versus Japanese-type surgery in gastric cancer
77. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial
78. Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial
79. Lymphadenectomy and pancreatico-splenectomy in gastric cancer surgery
80. Morbidity and mortality after D2 gastrectomy for gastric cancer: Results of the Italian Gastric Cancer Study Group prospective multicenter surgical study
81. Extended lymph node dissection for gastric cancer: Results of a prospective, multi-centre analysis of morbidity and mortality in 118 consecutive cases
82. Radical surgery
83. D2 gastrectomy: Lessons from a prospective audit of the learning curve
84. Should general surgeons treat gastric carcinoma? An audit of practice and results, 1980-1985
85. A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan
86. The effect of extended lymphadenectomy on survival in patients with gastric adenocarcinoma
87. Post-operative adjuvant 5-flurouracil plus methyl-CCNU therapy for gastric cancer patients
88. Adjuvant chemotherapy in operable gastric cancer. 5 Year follow up of first British Stomach Cancer Group trial
89. Adjuvant treatments following curative resection for gastric cancer
90. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: Five year follow up
91. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma
92. Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomised trials
93. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials
94. Multimodality therapy for completed resected R0 gastric cancer
95. Postoperative combined radiation and chemotherapy improves disease free survival and overall survival in resected adenocarcinoma of the stomach and GE junction. Results of Intergroup study 0116
96. Adjuvant and neoadjuvant therapy for gastric cancer
97. Randomised controlled trials on adjuvant therapy for gastric cancer: Japanese experience
98. Adjuvant therapy of gastric cancer: The Japanese experience
99. Adjuvant therapy for gastric carcinoma patients in the past 15 years: A review of western and oriental trials
100. Adjuvant mitomycin and flurouracil followed by oral uracil plus tegafur in serosa negative gastric cancer: A randomised trial. Gastric cancer study group
101. Effectiveness of immunochemotherapy for gastric cancer: A review of the current status